CD274 and neoplasm: Tumor-infiltrating immune cells in the tumor microenvironment, gene analysis such as microsatellite instability, mismatch-repair deficiency, and tumor mutation burden may be important in predicting clinical benefits of PD-1/PD-L1 checkpoint blockades [13].